Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in AD
- PDF / 684,625 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 30 Downloads / 188 Views
RESEARCH
Open Access
Gene therapy in rare diseases: the benefits and challenges of developing a patientcentric registry for Strimvelis in ADA-SCID Heide Stirnadel-Farrant1*, Mahesh Kudari2, Nadia Garman1, Jessica Imrie3, Bikramjit Chopra2, Stefania Giannelli4, Michela Gabaldo4, Ambra Corti4, Stefano Zancan4, Alessandro Aiuti4,5,6, Maria Pia Cicalese4,5, Rohit Batta2, Jonathan Appleby1, Mario Davinelli7 and Pauline Ng2
Abstract Background: Strimvelis (autologous CD34+ cells transduced to express adenosine deaminase [ADA]) is the first ex vivo stem cell gene therapy approved by the European Medicines Agency (EMA), indicated as a single treatment for patients with ADA-severe combined immunodeficiency (ADA-SCID) who lack a suitable matched related bone marrow donor. Existing primary immunodeficiency registries are tailored to transplantation outcomes and do not capture the breadth of safety and efficacy endpoints required by the EMA for the long-term monitoring of gene therapies. Furthermore, for extended monitoring of Strimvelis, the young age of children treated, small patient numbers, and broad geographic distribution of patients all increase the risk of loss to follow-up before sufficient data have been collected. Establishing individual investigator sites would be impractical and uneconomical owing to the small number of patients from each location receiving Strimvelis. Results: An observational registry has been established to monitor the safety and effectiveness of Strimvelis in up to 50 patients over a minimum of 15 years. To address the potential challenges highlighted above, data will be collected by a single investigator site at Ospedale San Raffaele (OSR), Milan, Italy, and entered into the registry via a central electronic platform. Patients/families and the patient’s local physician will also be able to submit healthcare information directly to the registry using a uniquely designed electronic platform. Data entry will be monitored by a Gene Therapy Registry Centre (funded by GlaxoSmithKline) who will ensure that necessary information is collected and flows between OSR, the patient/family and the patient’s local healthcare provider. Conclusion: The Strimvelis registry sets a precedent for the safety monitoring of future gene therapies. A unique, patient-focused design has been implemented to address the challenges of long-term follow-up of patients treated with gene therapy for a rare disease. Strategies to ensure data completeness and patient retention in the registry will help fulfil pharmacovigilance requirements. Collaboration with partners is being sought to expand from a treatment registry into a disease registry. Using practical and cost-efficient approaches, the Strimvelis registry is hoped to encourage further innovation in registry design within orphan drug development. Keywords: Adenosine deaminase deficiency, Severe combined immunodeficiency, Gene therapy, Haematopoietic stem cell transplantation, Transplantation, Autologous, Pharmacovigilance
* Correspondence: [email protected] 1
Data Loading...
